We report here the performance of a recently commercialized radioimmunoassay kit for determining erythropoietin (EPO) in serum or plasma. The lower detection limit of the method was 3 U/L. Precision, analyzed by the variation coefficients between different assay runs and in the same experiment, was always <10%; accuracy was assessed by recovery and dilution tests. In anemic patients (hematocrit 18-39%), the concentration of EPO was logarithmically related to hematocrit. A relatively large dispersion of the results was noted, as reported by others with various RIAs.
Materials and Methods

Methods
The RIA for EPO is based on the competition between EN) in serum (or plasma) and pure recombinant iodinated EPO, for a rabbit antibody raised against purified human urinary erythropoietin.
We used the RIA kit developed by Briefly, duplicate 200-jzL samples of standard human recombinant EPO (10-260 U/L) or of unknown serum are preincubated with a rabbit-specific antibody (100 L) for 2 h at room temperature. After adding 1251-labeled recombinant EPO and incubating the mixture for 16-24 h at 4#{176}C, we added the precipitating reagent (containing normal rabbit serum, goat anti-rabbit serum, and surfactant) and then, 30 mm later, centrifuged the tubes and their contents. The amount of radioactivity in the pellet is counted for 1 mm with a gamma-scintillation counter. As previously shown (9), either serum or plasma samples can be processed, whatever the anticoagulant used; EPO can be determined within three months after collection, if samples are stored at -20 #{176}C. Because only 1 mL of serum or plasma is required, studies in pediatric departments may be feasible.
Patients
We studied 51 normal subjects without anemia [hematocrit (Ht) 39-49%] and 77 patients with polycythemia vera (PV), diagnosed according to the Polycythemia Vera Study Group criteria (11): some (n = 51) at diagnosis or at relapse (Ht 51%) and some (n = 26) in remission after chemo-or radiotherapy (Ht 40-50%). In all cases we measured erythrocyte and plasma volumes at the time that we collected venous blood for determining EPO concentration. Fifty-seven patients sent to the Nuclear Medicine De- In an additional 27 cases, erythrocyte and plasma volumes were measured in patients with myeloma, macroglobulmnemia, or lymphoma, to discriminate between plasma volume excess and erythrocyte volume deficit in the mechanism of the anemia; we measured the EN) titer on the same day.
Results AnalyticalPerformances
Sensitivity.
We Figure 1 (rht).
A spline curve-fitting method is used for data evaluation. Figure 1 (left) depicts the precision profile of the standard curve. Within-and between-assay CVs are <10% for EN) values between 12 and 150 U/L and 12 and 100 U/L, respectively. Table 1 shows that intra-and interassay CVs for EN) measurement in serum are 9% over the whole range of standardization (10-250 U/L). For this study, normal and pathological sera were pooled at different concentrations of EN) and then aliquoted and stored at -20 #{176}C. The aliquots were measured over a three-month period. Congealing of sera at -20 #{176}C does not affect the measured EPO concentration.
Linearity. We assessed linearity of the test by dilution and recovery tests. Three sera with different concentrations of EN) were diluted in zero standard; in addition, one serum was diluted in a serum with an undetectable
value of EN) (Figure 2). Dilutions in zero standard
give linear curves that go through the x-and y-axis intercept.
For samples diluted in a serum with an undetectable EN) value, the linearity of the dilution curves was still acceptable. 
Clinical Results
Normal subjects. For 51 normal subjects (Ht 39-49%) the mean EPO value in serum was 13.5 U/L (range 10-2( U/L). The 95% confidence interval (i.e., mean ± 2SD) wa 8.7-18.3 U/L. We did not find any difference related to agi or sex.
Normal values of EPO measured by RIA and reporte elsewhere are listed in Table 2 .
Chronic anemias. In 79 patients with chronic anemia bu without malignant or renal diseases, we observed a loga rithmic relation between the plasma EN) values and th Ht value (Figure 4) In the patients with severe renal failure, EN) was low or even very low (<6 UIL), whatever the degree of anemia Figure 4 ). For about half of the patients with malignant tiseases,
EN) values were statistically lower than exected from the Ht values (not shown).
PVpatients.
We studied 51 cases with Ht between 51% Lad70%. In this group, the mean ± SD EN) concentration vas 7.2 ± 2.4 U/L, with a single case >12 U/L. No orrelation was found between EPO concentration and ither Ht excess or blood volume.
We investigated
PV patients in clinical remission induced by 32P or hydroxyurea),
with Ht between 40% and 0%. The mean ± SD EPO value was 8.9 ± 3.6 U/L. EN) oncentrations were >12 UIL in only three cases. (Table 2) .
The method has a good sensitivity; it can detect an EPO concentration of 3 U/L in serum, which is less than the EPO concentration in normal serum. This method is also accurate, with recovery and dilution tests exhibiting a good correlation between the calculated and the observed EN)
concentrations.
Furthermore, CVs were always <10%. For both methods (bioassay and radioiinmunoassay), a logarithmic relationship was found between the EN) titer and Ht or hemoglobin concentration (5,9,10,12-20) , with a large scatter around the regression line. Our results also exhibit logarithmic regression, with a slope similar to the data published elsewhere (6, 9, 10,20) .
Some anemias, especially in renal deficiency, may be related to a decreased production of EN). As expected, in 14 cases of chronic renal failure, whatever the severity of anemia, a low EN) value was observed. What is the clinical benefit of EPO determination in renal failure anemia? Could the concentrations of EN) be used to distinguish between anemias caused by a defect in EN) production and other mechanisms (21) and therefore to help forecast the clinical effectiveness of EN) therapy? Only a large-scale study, possible with a simple and fast RIA like the one described here, can answer these questions. A possible defect in EPO production has been suggested as one of the main causes of anemia in malignant diseases (3, 10), in chronic rheumatic disorders (22, 23) PE (4, 12, 19) .
Nevertheless, PE is not a homogeneous syndrome, except in well-characterized "secondary" cases. Many of these cases follow a chronic evolution, with further appearance of one or another symptom similar to those observed in PV. In some patients with PE, the kinetics of the stem cells exhibit the same EN) hypersensitivity as is observed in PV (27-29). In PE patients, EN) concentrations generally are much higher than in the normal group, but sometimes lower (or subnormal), suggesting a "primary" erythrocyte production disorder. From these data the EN) concentrations should be determined by RIA in every new case of PE. The growth kinetics of stem cells should be investigated in cases with no hypoxia or tumor, but presenting normal or low EPO values.
None of the identified PV cases (i.e., the patients with classical criteria of this disease) exhibited EN) values >17 UIL, even when a slight anemia occurred secondary to their treatment.
This contrasts with a previous suggestion that EPO values increase after therapy (5). Koeffier and Goldwasser (12) suggested a cutoff value of 30 UIL to discriminate between primary and secondary erythrocytosis. From our present data, a limit of 14 U/L includes 98% of the PV cases (100% of the cases with Ht >50%) and excludes 86% of the PE cases. In conclusion, the measurement of the EPO concentration in serum is useful in the biological discrimination between polycythemia vera and erythrocytosis.
A largescale study of EN) concentration is now possible with radioimmunoassays, to assess its clinical usefulness in various pathologies.
